8-K: Silence Therapeutics Shareholders Approve All 13 Resolutions at 2025 Annual General Meeting

Silence Therapeutics plc announced that all thirteen resolutions, including director re-appointments and auditor ratifications, were duly passed by shareholders at its 2025 Annual General Meeting held on June 26, 2025.

Summary

• Silence Therapeutics plc held its 2025 Annual General Meeting of Shareholders (AGM) on June 26, 2025, where all thirteen proposed resolutions were voted on and duly passed.
• Shareholders re-appointed four directors: David Lemus, Tim McInerney, Iain Ross, and Craig Tooman.
• The compensation of the company's named executive officers for 2024 was approved on an advisory basis.
• Shareholders indicated a preference for annual advisory votes on executive compensation, with 77,681,083 votes for 'One Year' frequency, leading the company to adopt an annual schedule for these votes.
• PricewaterhouseCoopers LLP was ratified as the U.S. independent registered public accounting firm for the year ending December 31, 2025, and re-appointed as the U.K. statutory auditors.
• The Audit & Risk Committee was authorized to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2025.
• The company's U.K. statutory annual accounts and reports for the year ended December 31, 2024, were received and adopted.
• The directors' remuneration report for the year ended December 31, 2024, was approved.
• The application of Article 159 of the company's articles of association was approved.
• A special resolution to adopt new draft articles of association, replacing the existing ones, was passed.

Sentiment

Score: 8

Explanation: All proposed resolutions at the Annual General Meeting were passed, demonstrating strong overall shareholder support for the company's governance and strategic direction, including the re-appointment of directors and approval of key reports. While some resolutions had higher 'Against' or 'Abstain' votes, they still passed comfortably, indicating a stable corporate governance environment.

Positives

• All thirteen resolutions presented at the AGM were duly passed by shareholders, indicating strong overall support for the company's proposals.
• The re-appointment of all four directors (David Lemus, Tim McInerney, Iain Ross, and Craig Tooman) demonstrates continued shareholder confidence in the current board.
• Shareholders overwhelmingly supported holding future advisory votes on executive compensation on an annual basis, aligning with the board's recommendation and promoting regular oversight.
• The ratification and re-appointment of PricewaterhouseCoopers LLP as auditors for both U.S. and U.K. operations ensures continuity in financial oversight.

Negatives

• While passed, Resolution 11, concerning the approval of the directors' remuneration report for 2024, received 1,838,213 'Against' votes and 5,620,278 'Abstain' votes, indicating some shareholder dissent or reservations regarding executive compensation.
• Resolution 13, the special resolution to adopt new articles of association, also saw a significant number of 'Abstain' votes (5,625,006), suggesting some shareholders opted not to take a definitive stance on this governance change.

Future Outlook

The company has determined to hold future non-binding advisory votes to approve the compensation of its named executive officers on an annual basis until the next required non-binding advisory vote on the frequency of holding future votes regarding executive compensation.

Industry Context

This filing is a routine corporate governance update detailing the results of the company's Annual General Meeting. It does not contain information directly related to broader industry trends or competitive landscape shifts within the biotechnology or pharmaceutical sectors.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: All resolutions passed, providing clarity on corporate governance and management. The decision to hold annual advisory votes on executive compensation aligns with majority shareholder preference, enhancing their voice.
• Management/Directors: The re-appointment of directors indicates continued confidence from shareholders. The advisory approval of executive compensation provides a mandate for current remuneration practices.
• Auditors: PricewaterhouseCoopers LLP's re-appointment ensures continuity and stability in the company's auditing processes for both U.S. and U.K. statutory requirements.

Next Steps

• The company will hold future non-binding advisory votes on the compensation of its named executive officers on an annual basis.
• PricewaterhouseCoopers LLP will continue to hold office as the U.K. statutory auditors until the conclusion of the next annual general meeting of shareholders.
• The Audit & Risk Committee is authorized to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2025.
• The newly adopted articles of association are effective from the conclusion of the 2025 AGM.

Key Dates

Recommendation

Keywords

Silence Therapeutics, SLN, SEC Filing, 8-K, Annual General Meeting, AGM, Shareholder Vote, Corporate Governance, Director Re-appointment, Auditor Appointment, Executive Compensation, Articles of Association, Biotechnology, Pharmaceuticals